LLRAPC Newsletter – February 2026(691 KB) - LMSG/LLR APC newsletters
Date added: 11th Mar 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| TIRZEPATIDE (Mounjaro®) (UPDATED) | Green | Management of overweight and obesity |
For managing overweight and obesity in adults in line with NICE TA1026. March 2026: Green for eligible cohort only as per LLR weight management guide or access via LLR specialist weight loss clinic |
| BUDESONIDE / FORMOTEROL (Symbicort 100/3 pMDI®) (NEW) | Green | Asthma |
– Restricted for use in children 12 to 17 years old with asthma in line with LLR guidelines when an aerosol device is required – Children 5-11 years old only under secondary / tertiary asthma care where this may be started as MART regimen with spacer under specialist supervision. This can be continued in primary care. COPD: Not licensed
|
| CALCIUM POLYSTYRENE SULPHONATE (Calcium Resonium®) (UPDATED) | Red |
Monitor serum-calcium as patients with chronic renal failure may experience a sudden rise in serum-calcium. |
|
| CAPTOPRIL (NEW) | Red | For Acute Scleroderma renal crisis when haemodynamically unstable |
Once stable to switch to longer acting ACE inhibitor |
| Dexcom ONE® and Dexcom ONE+® (UPDATED) | Yellow | Diabetes Continuous glucose monitoring (CGM) |
Dexcom ONE® and Dexcom ONE+ ® are approved for use in Leicester, Leicestershire and Rutland for diabetes glucose monitoring where a patient meets the criteria detailed in the LLR APC position statement. Dexcom ONE® will be discontinued on 31st March 2026 and therefore all patients using this device should be switched over to the updated Dexcom ONE+. All new patients must be started on Dexcom ONE+ |
| FLUTICASONE PROPIONATE / SALMETEROL (Seretide Evohaler®) (UPDATED) | Green | Asthma |
Asthma: NOT RECOMMENDED IN ADULTS 50/25 – For children 4 years and over only when an aerosol device is required. 125/25 – For 12-17 year olds only when increased dose of ICS indicated and an aerosol device is required. Must not be used for AIR or MART regimens COPD: Not licensed |
| Freestyle Libre 2 Plus® (UPDATED) | Yellow | Diabetes Continuous glucose monitoring (CGM) |
Freestyle Libre 2 Plus® is approved for use in LLR for diabetes glucose monitoring where a patient meets the criteria detailed in the LLR APC position statement.
|
| HYDRALAZINE (UPDATED) | Yellow | Hypertension & Heart Failure | |
| Inbrija | Yellow | Indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor (1) | |
| OMEPRAZOLE DISPERSIBLE (UPDATED) | Green |
2nd line choice dispersible PPI |
|
| SODIUM POLYSTYRENE SULPHONATE (Resonium A®) (UPDATED) | Red |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLR APC Minutes 2025(3 MB) - LMSG/LLR APC minutes
Date added: 9th Mar 2026
LLR APC Meeting Minutes – February 2026(423 KB) - LMSG/LLR APC minutes
Date added: 9th Mar 2026
Leflunomide Rheumatology Shared Care Request Form National Format(69 KB)
Date added: 5th Mar 2026
Mycophenolate Rheumatology Shared Care Request Form National Format(69 KB)
Date added: 5th Mar 2026
Mycophenolate Dermatology Shared Care Request Form National Format(69 KB)
Date added: 5th Mar 2026
Mycophenolate Neurology Shared Care Request Form National Format(68 KB)
Date added: 5th Mar 2026
Mycophenolate Respiratory Shared Care Request Form National Format(69 KB)
Date added: 5th Mar 2026
Methotrexate Rheumatology Request Form(70 KB)
Date added: 5th Mar 2026
Methotrexate Adult Gastroenterology Request Form(69 KB)
Date added: 5th Mar 2026
Methotrexate dermatology request form(69 KB)
Date added: 5th Mar 2026
LLR APC Newsletter December 2025 / January 2026(582 KB) - LMSG/LLR APC newsletters
Date added: 19th Feb 2026
Diabetic Foot Infection(166 KB)
Date added: 13th Feb 2026
Acute Diverticulitis(202 KB)
Date added: 13th Feb 2026
Acute Pyelonephritis in Adults(235 KB)
Date added: 13th Feb 2026
PHARYNGITIS / SORE THROAT / TONSILLITIS(168 KB)
Date added: 13th Feb 2026
Methotrexate Rheumatology/Dermatology/Gastroenterology SCA(523 KB) - Shared care agreement
Date added: 29th Dec 2022
Continence Prescribing Formulary for LLR(624 KB) - Guidelines
Date added: 9th Aug 2018
Leflunomide Shared Care Agreement(465 KB) - Shared care agreement
Date added: 4th May 2016
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more